Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
2003 1
2005 2
2006 2
2007 3
2008 4
2011 1
2012 2
2013 1
2014 1
2015 1
2016 1
2020 1
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Labor-associated eosinophilic gastroenteritis.
Park SJ, Kenny PR, Palekar NA. Park SJ, et al. Among authors: palekar na. Mil Med. 2012 Jan;177(1):99-100. doi: 10.7205/milmed-d-11-00201. Mil Med. 2012. PMID: 22338989
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Extrahepatic manifestations of hepatitis C.
Palekar NA, Harrison SA. Palekar NA, et al. South Med J. 2005 Oct;98(10):1019-23. doi: 10.1097/01.smj.0000182873.62872.22. South Med J. 2005. PMID: 16295816 Review.
Hyperbaric Oxygen Therapy in Chronic Inflammatory Conditions of the Pouch.
Hasan B, Yim Y, Ur Rashid M, Khalid RA, Sarvepalli D, Castaneda D, Ur Rahman A, Palekar N, Charles R, Castro FJ, Shen B. Hasan B, et al. Among authors: palekar n. Inflamm Bowel Dis. 2021 Jun 15;27(7):965-970. doi: 10.1093/ibd/izaa245. Inflamm Bowel Dis. 2021. PMID: 32944766
Serotonin syndrome with ziprasidone and sertraline.
Palekar N, Eisman J. Palekar N, et al. J Neuropsychiatry Clin Neurosci. 2013 Spring;25(2):E1. doi: 10.1176/appi.neuropsych.12040082. J Neuropsychiatry Clin Neurosci. 2013. PMID: 23686039 No abstract available.
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA, Leighton JA, Katz JA, Cohen RD, Gerich ME, Cross RK, Higgins PDR, Tinsley A, Glover S, Siegel CA, Bohl JL, Iskandar H, Ji J, Hu L, Sands BE. Cohen BL, et al. Among authors: palekar n. Gastroenterology. 2022 Jul;163(1):204-221. doi: 10.1053/j.gastro.2022.03.057. Epub 2022 Apr 10. Gastroenterology. 2022. PMID: 35413359
26 results